Disc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
Follow IRON
Alert me
Disc Medicine, Inc. (IRON) Free cash flow
Disc Medicine, Inc.'s free cash flow for fiscal 2025 was −$181.3M, compared with −$94.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$197.5M. Over the past ten years it has ranged from −$181.3M (fiscal 2025) to −$27.5M (fiscal 2021) — the current reading is the lowest in ten years. Free cash flow has fallen for 6 consecutive fiscal years. Disc Medicine, Inc. ranks 540th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$181.3M | — |
| FY2024 | −$94.4M | — |
| FY2023 | −$73.6M | — |
| FY2022 | −$42.4M | — |
| FY2022 | −$42.3M | — |
| FY2021 | −$27.6M | — |
| FY2021 | −$27.5M | — |
| FY2020 | −$32.7M | — |
| FY2020 | −$32.7M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$44.2M | — |
| Mar 2026 | −$62.2M | — |
| Dec 2025 | −$43.3M | — |
| Sep 2025 | −$47.8M | — |
| 22 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $82.0M |
| PBLS Parabilis Medicines, Inc. compare | −$119.1M |
| TNGX Tango Therapeutics, Inc. compare | −$144.2M |
| IRON Disc Medicine, Inc. | −$197.5M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$216.1M |
| XENE Xenon Pharmaceuticals Inc. compare | −$338.5M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$480.4M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)